OPEN END TURBO OHNE STOP-LOSS - FRESENIUS MEDICAL CARE Stock

Certificat

DE000LS2U9D2

Real-time Bid/Ask 11:47:42 2024-05-22 EDT
3.98 EUR / 4.01 EUR +2.44% Intraday chart for OPEN END TURBO OHNE STOP-LOSS - FRESENIUS MEDICAL CARE
Current month-3.23%
1 month-10.14%
Date Price Change
24-05-22 3.97 +1.79%
24-05-21 3.9 +2.63%
24-05-20 3.8 0.00%
24-05-17 3.8 0.00%
24-05-16 3.8 +0.53%

Delayed Quote Börse Stuttgart

Last update May 22, 2024 at 11:36 am

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellPUT
Underlying FRESENIUS MEDICAL CARE AG
Issuer Lang & Schwarz
WKN LS2U9D
ISINDE000LS2U9D2
Date issued 2017-06-16
Strike 77.1
Maturity Unlimited
Parity 10 : 1
Emission price 1.78
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 5.92
Lowest since issue 1.02
Spread 0.03
Spread %0.75%

Company Profile

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based Company, which is a kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.
Sector
-
More about the company

Ratings for Fresenius Medical Care AG

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Fresenius Medical Care AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
39.6 EUR
Average target price
39.84 EUR
Spread / Average Target
+0.61%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW